TVRD
Tvardi Therapeutics, Inc.
Price Chart
Latest Quote
$2.58
-0.05 (-1.90%)
Current Price
| Previous Close | $2.63 |
| Open | $2.69 |
| Day High | $2.75 |
| Day Low | $2.56 |
| Volume | 67,789 |
Stock Information
| Shares Outstanding | 9.38M |
| Total Debt | $174K |
| Cash Equivalents | $24.98M |
| Net Income | $-15.44M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $24.20M |
| EPS (TTM) | $-0.27 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-134K |
| Income | $-15.44M |
| Book/sh | $1.55 |
| Cash/sh | $2.66 |
| Employees | 12 |
Financial Ratios
| Quick Ratio | 2.22 |
| Current Ratio | 2.25 |
| Debt/Eq | 1.20 |
Returns & Margins
| ROA | -68.64% |
Ownership
| Insider Ownership | 34.64% |
| Institutional Ownership | 28.93% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.89 |
| P/B | 1.67 |
Analyst Data
| Recommendation | buy |
| Target Price | $8.29 |
Technical Indicators
| SMA20 | $3.07 |
| SMA50 | $3.30 |
| SMA200 | $8.59 |
| RSI | 13.60 |
| ATR | 0.2126 |
| Shares Float | 6.46M |
| Short Float | 4.67% |
| Short Ratio | 8.97 |
| Rel Volume | 1.18 |
Performance History
| Week | -4.44% |
| Month | -35.50% |
| Quarter | -25.00% |
| 6 Months | -38.86% |
| YTD | -36.76% |
| Year | -89.66% |
| 3 Years | -97.89% |
| 5 Years | -99.48% |
| 10 Years | -98.61% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $2.58 | 67,800 |
| 2026-06-16 | $2.63 | 39,700 |
| 2026-06-15 | $2.67 | 73,000 |
| 2026-06-12 | $2.64 | 36,800 |
| 2026-06-11 | $2.71 | 36,000 |
| 2026-06-10 | $2.70 | 53,600 |
| 2026-06-09 | $2.78 | 67,900 |
| 2026-06-08 | $2.85 | 77,600 |
| 2026-06-05 | $2.89 | 81,000 |
| 2026-06-04 | $3.08 | 33,400 |
| 2026-06-03 | $2.95 | 56,800 |
| 2026-06-02 | $3.17 | 39,300 |
| 2026-06-01 | $3.22 | 90,600 |
| 2026-05-29 | $3.38 | 54,300 |
| 2026-05-28 | $3.49 | 53,100 |
| 2026-05-27 | $3.30 | 77,100 |
| 2026-05-26 | $3.44 | 55,600 |
| 2026-05-22 | $3.57 | 48,500 |
| 2026-05-21 | $3.59 | 58,600 |
| 2026-05-20 | $3.85 | 51,800 |
| 2026-05-19 | $3.71 | 34,700 |
| 2026-05-18 | $4.00 | 66,900 |
About Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
đ° Latest News
Sector Update: Health Care Stocks Fall Late Afternoon
MT Newswires âĸ 2026-04-20T19:55:23ZWe're Keeping An Eye On Tvardi Therapeutics' (NASDAQ:TVRD) Cash Burn Rate
Simply Wall St. âĸ 2026-02-07T13:48:02Z
Tvardi (TVRD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Zacks âĸ 2025-11-18T14:55:02Z
Tvardi: Q3 Earnings Snapshot
Associated Press Finance âĸ 2025-11-13T21:08:55ZHere's Why Tvardi (TVRD) Is a Great 'Buy the Bottom' Stock Now
Zacks âĸ 2025-10-28T13:55:02Z
Down 83.0% in 4 Weeks, Here's Why Tvardi (TVRD) Looks Ripe for a Turnaround
Zacks âĸ 2025-10-16T13:35:02Z
TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals
Zacks âĸ 2025-10-14T15:24:00Z
AstraZeneca cuts US drug pricing deal; FDA declares Novo plant out of compliance
BioPharma Dive âĸ 2025-10-14T11:53:00Z
Why Tvardi Therapeutics (TVRD) Is Down 83.3% After Disappointing Phase 2 TTI-101 IPF Trial Results
Simply Wall St. âĸ 2025-10-14T08:10:47Z
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) most popular amongst retail investors who own 57% of the shares, institutions hold 26%
Simply Wall St. âĸ 2025-10-11T12:00:28Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $26,748,000 | $28,107,000 | $18,665,000 | $21,193,000 |
| Other Income Expense | $7,159,000 | $-2,037,000 | - | - |
| Other Non Operating Income Expenses | $7,159,000 | $-2,037,000 | - | - |
| Net Non Operating Interest Income Expense | $1,375,000 | $747,000 | $1,318,000 | $651,000 |
| Operating Expense | $26,748,000 | $28,107,000 | $18,665,000 | $21,193,000 |
| General And Administrative Expense | $8,737,000 | $4,457,000 | $2,799,000 | $2,727,000 |
| Interest Expense | - | - | $0 | $3,000 |
| Interest Expense Non Operating | - | - | $0 | $3,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-18,214,000 | $-29,397,000 | $-17,347,000 | $-20,542,000 |
| Net Interest Income | $1,375,000 | $747,000 | $1,318,000 | $651,000 |
| Interest Income | $1,375,000 | $747,000 | $1,318,000 | $654,000 |
| Normalized Income | $-18,214,000 | $-29,397,000 | $-17,347,000 | $-20,542,000 |
| Net Income From Continuing And Discontinued Operation | $-18,214,000 | $-29,397,000 | $-17,347,000 | $-20,542,000 |
| Total Operating Income As Reported | $-26,748,000 | $-28,107,000 | $-18,665,000 | $-21,193,000 |
| Net Income Common Stockholders | $-18,214,000 | $-29,397,000 | $-17,347,000 | $-20,542,000 |
| Net Income | $-18,214,000 | $-29,397,000 | $-17,347,000 | $-20,542,000 |
| Net Income Including Noncontrolling Interests | $-18,214,000 | $-29,397,000 | $-17,347,000 | $-20,542,000 |
| Net Income Continuous Operations | $-18,214,000 | $-29,397,000 | $-17,347,000 | $-20,542,000 |
| Pretax Income | $-18,214,000 | $-29,397,000 | $-17,347,000 | $-20,542,000 |
| Interest Income Non Operating | $1,375,000 | $747,000 | $1,318,000 | $654,000 |
| Operating Income | $-26,748,000 | $-28,107,000 | $-18,665,000 | $-21,193,000 |
| Per Share | ||||
| Diluted EPS | $-3.26 | $-11.41 | $-6.74 | $-7.98 |
| Basic EPS | $-2.46 | $-11.41 | $-6.74 | $-7.98 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-26,653,000 | $-28,012,000 | $-17,252,000 | $-20,454,000 |
| Reconciled Depreciation | $95,000 | $95,000 | $95,000 | $85,000 |
| EBITDA (Bullshit earnings) | $-26,653,000 | $-28,012,000 | $-17,252,000 | $-20,454,000 |
| EBIT | $-26,748,000 | $-28,107,000 | $-17,347,000 | $-20,539,000 |
| Diluted Average Shares | $7,783,182 | $2,575,462 | $2,575,462 | $2,575,462 |
| Basic Average Shares | $7,404,065 | $2,575,462 | $2,575,462 | $2,575,462 |
| Diluted NI Availto Com Stockholders | $-18,214,000 | $-29,397,000 | $-17,347,000 | $-20,542,000 |
| Research And Development | $18,011,000 | $23,650,000 | $15,866,000 | $18,466,000 |
| Selling General And Administration | $8,737,000 | $4,457,000 | $2,799,000 | $2,727,000 |
| Other Gand A | $8,737,000 | $4,457,000 | $2,799,000 | $2,727,000 |
Fetched: 2026-06-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $20,624,000 | $-91,516,000 | $-62,506,000 | $-45,562,000 |
| Total Assets | $32,073,000 | $35,199,000 | $27,001,000 | $45,097,000 |
| Total Non Current Assets | $535,000 | $3,513,000 | $843,000 | $988,000 |
| Other Non Current Assets | $17,000 | $17,000 | $17,000 | $17,000 |
| Non Current Deferred Assets | $0 | $2,811,000 | - | - |
| Goodwill And Other Intangible Assets | $322,000 | $385,000 | $448,000 | $511,000 |
| Other Intangible Assets | $322,000 | $385,000 | $448,000 | $511,000 |
| Current Assets | $31,538,000 | $31,686,000 | $26,158,000 | $44,109,000 |
| Prepaid Assets | $727,000 | $72,000 | $3,239,000 | $370,000 |
| Cash Cash Equivalents And Short Term Investments | $30,811,000 | $31,614,000 | $22,919,000 | $43,739,000 |
| Cash And Cash Equivalents | $20,734,000 | $31,614,000 | $22,919,000 | $21,489,000 |
| Debt | ||||
| Total Debt | $201,000 | $30,563,000 | $368,000 | $450,000 |
| Long Term Debt And Capital Lease Obligation | $85,000 | $30,460,000 | $275,000 | $368,000 |
| Current Debt And Capital Lease Obligation | $116,000 | $103,000 | $93,000 | $82,000 |
| Long Term Debt | - | $30,259,000 | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $11,127,000 | $126,330,000 | $89,059,000 | $90,148,000 |
| Total Non Current Liabilities Net Minority Interest | $85,000 | $115,963,000 | $85,778,000 | $85,871,000 |
| Current Liabilities | $11,042,000 | $10,367,000 | $3,281,000 | $4,277,000 |
| Payables And Accrued Expenses | $9,629,000 | $9,122,000 | $2,246,000 | $3,517,000 |
| Payables | $3,219,000 | $2,186,000 | $1,611,000 | $2,409,000 |
| Accounts Payable | $3,219,000 | $2,186,000 | $1,611,000 | $2,409,000 |
| Equity | ||||
| Common Stock Equity | $20,946,000 | $-91,131,000 | $-62,058,000 | $-45,051,000 |
| Total Equity Gross Minority Interest | $20,946,000 | $-91,131,000 | $-62,058,000 | $-45,051,000 |
| Stockholders Equity | $20,946,000 | $-91,131,000 | $-62,058,000 | $-45,051,000 |
| Gains Losses Not Affecting Retained Earnings | $8,000 | $0 | $0 | $-24,000 |
| Other Equity Adjustments | $8,000 | - | - | $-24,000 |
| Retained Earnings | $-110,450,000 | $-92,236,000 | $-62,839,000 | $-45,492,000 |
| Preferred Securities Outside Stock Equity | $0 | $85,503,000 | $85,503,000 | $85,503,000 |
| Other | ||||
| Ordinary Shares Number | $9,381,344 | $9,355,542 | $9,355,542 | $9,355,542 |
| Share Issued | $9,381,344 | $9,355,542 | $9,355,542 | $9,355,542 |
| Tangible Book Value | $20,624,000 | $-91,516,000 | $-62,506,000 | $-45,562,000 |
| Invested Capital | $20,946,000 | $-60,872,000 | $-62,058,000 | $-45,051,000 |
| Working Capital | $20,496,000 | $21,319,000 | $22,877,000 | $39,832,000 |
| Capital Lease Obligations | $201,000 | $304,000 | $368,000 | $450,000 |
| Total Capitalization | $20,946,000 | $-60,872,000 | $-62,058,000 | $-45,051,000 |
| Additional Paid In Capital | $131,379,000 | $1,103,000 | $762,000 | $446,000 |
| Capital Stock | $9,000 | $2,000 | $19,000 | $19,000 |
| Common Stock | $9,000 | $2,000 | $19,000 | $19,000 |
| Long Term Capital Lease Obligation | $85,000 | $201,000 | $275,000 | $368,000 |
| Current Capital Lease Obligation | $116,000 | $103,000 | $93,000 | $82,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $1,297,000 | $1,142,000 | $942,000 | $678,000 |
| Current Accrued Expenses | $6,410,000 | $6,936,000 | $635,000 | $1,108,000 |
| Net PPE | $196,000 | $300,000 | $378,000 | $460,000 |
| Gross PPE | $196,000 | $300,000 | $378,000 | $460,000 |
| Other Properties | $196,000 | $300,000 | $378,000 | $460,000 |
| Other Short Term Investments | $10,077,000 | $0 | $0 | $22,250,000 |
Fetched: 2026-06-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-23,499,000 | $-18,305,000 | $-21,040,000 | $-17,916,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-23,499,000 | $-18,305,000 | $-21,040,000 | $-17,866,000 |
| Cash Flow From Continuing Operating Activities | $-23,499,000 | $-18,305,000 | $-21,040,000 | $-17,866,000 |
| Investing Activities | ||||
| Investing Cash Flow | $-10,084,000 | $0 | $22,468,000 | $-22,000,000 |
| Cash Flow From Continuing Investing Activities | $-10,084,000 | $0 | $22,468,000 | $-22,000,000 |
| Capital Expenditure | - | - | - | $-50,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $532,000 | $5,000 | $2,000 | $4,000 |
| Financing Cash Flow | $22,703,000 | $27,000,000 | $2,000 | $4,000 |
| Cash Flow From Continuing Financing Activities | $22,703,000 | $27,000,000 | $2,000 | $4,000 |
| Net Other Financing Charges | $22,171,000 | $-1,303,000 | - | - |
| Net Common Stock Issuance | $532,000 | $5,000 | $2,000 | $4,000 |
| Common Stock Issuance | $532,000 | $5,000 | $2,000 | $4,000 |
| Other | ||||
| Issuance Of Debt | $0 | $28,298,000 | - | - |
| End Cash Position | $20,734,000 | $31,614,000 | $22,919,000 | $21,489,000 |
| Beginning Cash Position | $31,614,000 | $22,919,000 | $21,489,000 | $61,351,000 |
| Changes In Cash | $-10,880,000 | $8,695,000 | $1,430,000 | $-39,862,000 |
| Net Issuance Payments Of Debt | $0 | $28,298,000 | - | - |
| Net Long Term Debt Issuance | $0 | $28,298,000 | - | - |
| Long Term Debt Issuance | $0 | $28,298,000 | - | - |
| Net Investment Purchase And Sale | $-10,084,000 | $0 | $22,468,000 | $-21,950,000 |
| Sale Of Investment | $21,402,000 | $0 | $22,468,000 | $22,045,000 |
| Purchase Of Investment | $-31,486,000 | $0 | $0 | $-43,995,000 |
| Change In Working Capital | $508,000 | $8,641,000 | $-3,959,000 | $2,666,000 |
| Change In Other Current Liabilities | $-103,000 | $-93,000 | $-82,000 | $-7,000 |
| Change In Payables And Accrued Expense | $919,000 | $5,567,000 | $-1,008,000 | $2,195,000 |
| Change In Prepaid Assets | $-308,000 | $3,167,000 | $-2,869,000 | $478,000 |
| Other Non Cash Items | $723,000 | $230,000 | $51,000 | $34,000 |
| Stock Based Compensation | $1,399,000 | $319,000 | $314,000 | $246,000 |
| Unrealized Gain Loss On Investment Securities | $-7,810,000 | $1,807,000 | - | - |
| Amortization Of Securities | $-200,000 | $0 | $-194,000 | $-355,000 |
| Depreciation Amortization Depletion | $95,000 | $95,000 | $95,000 | $85,000 |
| Depreciation And Amortization | $95,000 | $95,000 | $95,000 | $85,000 |
| Net Income From Continuing Operations | $-18,214,000 | $-29,397,000 | $-17,347,000 | $-20,542,000 |
| Net PPE Purchase And Sale | - | - | $0 | $-50,000 |
| Purchase Of PPE | - | - | $0 | $-50,000 |
Fetched: 2026-06-15